Fig. 1

Cumulative probability plots at month 12. Plots show the cumulative probability for a %∆CDAI^a, b ACR-N^b, and c ∆HAQ-DI. ^aOne extreme value for %∆CDAI is not shown: tofacitinib monotherapy, %∆CDAI = 175%. ^bTen extreme values for ACR-N are not shown: tofacitinib monotherapy, ACR-N =  − 1700, − 200, − 167, − 160, and − 150; cumulative probability = 0.003, 0.006, 0.009, 0.013, 0.019; tofacitinib + MTX, ACR-N =  − 106, cumulative probability = 0.003; ADA + MTX, ACR-N =  − 463, − 167, − 158, and − 129; cumulative probability = 0.003, 0.006, 0.010, and 0.013. ∆, change from baseline; ACR20/50/70, American College of Rheumatology ≥ 20%, ≥ 50%, or ≥ 70% response rates; ACR-N, American College of Rheumatology response rate, where ACR is the percentage improvement from baseline in American College of Rheumatology components, and N represents the minimum percentage achieved by each patient; ADA, adalimumab; CDAI, Clinical Disease Activity Index; HAQ-DI, Health Assessment Questionnaire-Disability Index; MCID, minimum clinically important difference; MTX, methotrexate